Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Paratek Pharmaceuticals Inc PRTK

Healthcare Industrials Business Services
Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its commercial product, NUZYRA (omadacycline), is a once-daily oral and intravenous antibiotic for the treatment of adult... see more

Recent & Breaking News (NDAQ:PRTK)

Paratek Pharmaceuticals to Present at Two August 2020 Healthcare Conferences

GlobeNewswire August 5, 2020

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire August 3, 2020

Paratek Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 10, 2020

GlobeNewswire July 28, 2020

Paratek Pharmaceuticals Announces Change to Time of 2020 Annual Meeting of Stockholders

GlobeNewswire May 29, 2020

Paratek Pharmaceuticals to Present at Jefferies 2020 Virtual Healthcare Conference

GlobeNewswire May 28, 2020

Paratek Pharmaceuticals to Present at Bank of America Securities 2020 Health Care Conference

GlobeNewswire May 11, 2020

Paratek Pharmaceuticals Announces First Quarter 2020 Total Revenues of $7.9 Million including NUZYRA® (omadacycline) Net Sales of $7.3 Million

GlobeNewswire May 11, 2020

Paratek Pharmaceuticals to Report First Quarter 2020 Financial Results on May 11, 2020

GlobeNewswire April 30, 2020

Paratek Pharmaceuticals Announces Initiation of Funding from BARDA for All FDA Required Post-marketing Studies for NUZYRA? (omadacycline)

GlobeNewswire April 2, 2020

Paratek Pharmaceuticals Announces Initiation of Funding from BARDA for Security Requirements and U.S. Onshoring of the Manufacturing Supply Chain for NUZYRA? (omadacycline)

GlobeNewswire April 1, 2020

Paratek Pharmaceuticals Announces the Submission of the pre-Emergency Use Authorization Application to the FDA for NUZYRA? (omadacycline)

GlobeNewswire March 10, 2020

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire March 2, 2020

Paratek Pharmaceuticals to Present at the SVB Leerink 9th Annual Global Healthcare Conference

GlobeNewswire February 26, 2020

Paratek Pharmaceuticals Announces Full Year 2019 Total Revenues of $16.5 Million including NUZYRA® (omadacycline) Net Sales of $11.5 Million

GlobeNewswire February 25, 2020

Paratek Announces License Grant to Almirall for SEYSARA® (sarecycline) for Greater China Region

GlobeNewswire February 24, 2020

Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2019 Financial Results on February 25, 2020

GlobeNewswire February 13, 2020

Paratek Awarded BARDA Project BioShield Contract for NUZYRA®

GlobeNewswire December 18, 2019

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire December 2, 2019

Paratek Pharmaceuticals Generates Net Revenues of $3.9 Million in the Third Quarter of 2019

GlobeNewswire November 12, 2019

Paratek Pharmaceuticals to Report Third Quarter 2019 Financial Results on November 12, 2019

GlobeNewswire November 4, 2019